Case Studies
Forecasting a Commercially Viable T Cell Therapy Manufacturing Process
In this case study, a company requested help from ScaleReady to build business case for G-Rex®500M-CS bioreactors as the primary cell production platform for their autologous TCR T cell therapy pipeline. ScaleReady modeled operational costs
for an autologous TCR T cell therapy company using G-Rex bioreactors. This provided transparency into long-term commercial
viability of the ScaleReady platform.
Case Studies
GMP Cytokines Optimization for Closed System T Cell Therapy Manufacturing
In this case study, a company focused on autologous T cell therapies targeting solid tumor cancers was progressing into clinical trials and needed to transition from research-grade to GMP-grade cytokines. Concurrently they wanted to improve
their methods of cytokine supplementation to reduce cytokine waste, improve dose accuracy across lots, and
reduce process risk by defining methods for closed-system cytokine addition. ScaleReady detailed a plan to help them achieve these goals.
Videos
Future of T Cell Manufacturing using G-Rex Closed-system Bioreactors
This video animation demonstrates a vision toward the industrialization and automation of T cell therapy manufacturing using G-Rex Bioreactors.
Video was created by Wilson Wolf Manufacturing Corporation.
Video was created by Wilson Wolf Manufacturing Corporation.
Literature
G-Rex Closed-system Bioreactors
In this brochure you will learn how G-Rex bioreactors solve the limitations of flask and bag-based cell therapy manufacturing. In this brochure:
- G-Rex Bioreactor mechanism of action
- Benefits for cell therapy manufacturing
- GatheRex Cell Harvest Pump
- User testimonials
Videos
G-Rex – Revolutionizing Cell Therapy Manufacturing
In this video you will learn how G-Rex bioreactors solve the limitations of flask and bag-based cell therapy manufacturing. By providing cells with uninterrupted access to oxygen and nutrients, the G-Rex cell culture device is the only accessible cell expansion technology that linearly scales to meet the demands of cell therapy manufacturers.
Videos
On Demand Symposium: Defining Intelligent Scale-up and Scale-out
In this recorded symposium, cell therapy manufacturing leaders speak about defining and planning for intelligent commercial scale up and scale out. Recorded at ISCT 2021.
CUE, Literature
Cell Processing Systems Comparison Flyer
Compare Lovo and Cue system specifications and applications.
Literature
TcBuster Non-viral Genetic Engineering Flyer
TcBuster non-viral gene editing solves the bottlenecks facing viral vector-based editing, including supply chain, manufacturing time, and integration safety. In this flyer:
- How TcBuster works
- Comparison to viral tranduction
- Data on transposition efficiency and scalability
Literature
ExCellerate Media for Immune Cells
This flyer provides details and data for our T cell and NK cell versions of ExCellerate media.
CUE, Literature
Cue Cell Processing System Brochure
Cue Cell Processing System is the definitive instrument for small volume cell processing for cell therapy. In this brochure:
- Instrument Features
- Applications supported
- Customizable protocol design
Literature
ScaleReady Portfolio Overview
We’ve anticipated where cell therapy manufacturing needs to be and we’re the only solution for cost-effective and practical cell therapy scale-up. In this brochure:
- Portfolio introduction
- G-Rex Bioreactors and raw materials
- Cell processing instruments
Videos
Evolution of Tumor-specific T Cell Production
This video features Juan Vera, Chief Development Officer at Marker Therapeutics, discussing how Marker used G-Rex Bioreactors and the Lovo Cell Processing System to evolve and simplify manufacturing of its multiple tumor-associated antigen (MultiTAA) T cell therapy in anticipation of commercialization.
This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.
This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.